PURE Bioscience (PURE) 10-Q 15 Mar 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jan. 31, 2022	Mar. 15, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jan. 31, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--07-31
Entity File Number	001-14468
Entity Registrant Name	PURE Bioscience, Inc.
Entity Central Index Key	0001006028
Entity Tax Identification Number	33-0530289
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	9669 Hermosa Avenue
Entity Address, City or Town	Rancho Cucamonga
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91730
City Area Code	(619)
Local Phone Number	596-8600
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		87,873,141

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jan. 31, 2022	Jul. 31, 2021
Current assets
Cash and cash equivalents	$ 1,131,000	$ 2,390,000
Accounts receivable	206,000	368,000
Inventories, net	299,000	332,000
Restricted cash	75,000	75,000
Prepaid expenses	29,000	32,000
Total current assets	1,740,000	3,197,000
Property, plant and equipment, net	728,000	740,000
Patents, net	321,000	366,000
Total assets	2,789,000	4,303,000
Current liabilities
Accounts payable	425,000	593,000
Accrued liabilities	159,000	138,000
Loan payable		239,000
Total current liabilities	584,000	970,000
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.01 par value: 150,000,000 shares authorized, 87,873,141 shares issued and outstanding at January 31, 2022, and 87,223,141shares issued and outstanding at July 31, 2021	879,000	873,000
Additional paid-in capital	128,617,000	128,253,000
Accumulated deficit	(127,291,000)	(125,793,000)
Total stockholders’ equity	2,205,000	3,333,000
Total liabilities and stockholders’ equity	$ 2,789,000	$ 4,303,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jan. 31, 2022	Jul. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	87,873,141	87,223,141
Common stock, shares outstanding	87,873,141	87,223,141

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2022	Jan. 31, 2021
Total revenue	$ 416,000	$ 916,000	$ 917,000	$ 2,507,000
Cost of goods sold	182,000	363,000	354,000	1,004,000
Gross profit	234,000	553,000	563,000	1,503,000
Operating costs and expenses
Selling, general and administrative	1,093,000	1,054,000	2,150,000	2,100,000
Research and development	81,000	93,000	148,000	176,000
Total operating costs and expenses	1,174,000	1,147,000	2,298,000	2,276,000
Loss from operations	(940,000)	(594,000)	(1,735,000)	(773,000)
Other income (expense)
Gain on extinguishment of indebtedness, net	239,000		239,000
Interest expense, net	(1,000)	(1,000)	(2,000)	(2,000)
Total other income (expense)	238,000	(1,000)	237,000	(2,000)
Net loss	$ (702,000)	$ (595,000)	$ (1,498,000)	$ (775,000)
Basic and diluted net loss per share	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.01)
Shares used in computing basic and diluted net loss per share	87,873,141	87,179,607	87,652,761	87,126,279
Product [Member]
Total revenue	$ 415,000	$ 868,000	$ 912,000	$ 2,285,000
Royalty [Member]
Total revenue	$ 1,000	$ 48,000	$ 5,000	$ 222,000

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning Balance at Jul. 31, 2020	$ 871,000	$ 127,414,000	$ (123,474,000)	$ 4,811,000
Beginning balance, shares at Jul. 31, 2020	87,072,951
Share-based compensation expense - stock options		428,000		428,000
Share-based compensation expense - restricted stock units		42,000		42,000
Issuance of common stock upon the exercise of stock options	$ 2,000	(2,000)
Issuance of common stock upon the exercise of stock options, shares	150,190
Issuance of common stock for vested restricted stock units
Issuance of common stock for vested restricted stock units, shares
Net loss			(775,000)	(775,000)
Ending Balance at Jan. 31, 2021	$ 873,000	127,882,000	(124,249,000)	4,506,000
Ending balance, shares at Jan. 31, 2021	87,223,141
Beginning Balance at Oct. 31, 2020	$ 871,000	127,643,000	(123,654,000)	4,860,000
Beginning balance, shares at Oct. 31, 2020	87,072,951
Share-based compensation expense - stock options		220,000		220,000
Share-based compensation expense - restricted stock units		21,000		21,000
Issuance of common stock upon the exercise of stock options	$ 2,000	(2,000)
Issuance of common stock upon the exercise of stock options, shares	150,190
Net loss			(595,000)	(595,000)
Ending Balance at Jan. 31, 2021	$ 873,000	127,882,000	(124,249,000)	4,506,000
Ending balance, shares at Jan. 31, 2021	87,223,141
Beginning Balance at Jul. 31, 2021	$ 873,000	128,253,000	(125,793,000)	3,333,000
Beginning balance, shares at Jul. 31, 2021	87,223,141
Share-based compensation expense - stock options		328,000		328,000
Share-based compensation expense - restricted stock units		42,000		42,000
Issuance of common stock upon the exercise of stock options
Issuance of common stock upon the exercise of stock options, shares
Issuance of common stock for vested restricted stock units	$ 6,000	(6,000)
Issuance of common stock for vested restricted stock units, shares	650,000
Net loss			(1,498,000)	(1,498,000)
Ending Balance at Jan. 31, 2022	$ 879,000	128,617,000	(127,291,000)	2,205,000
Ending balance, shares at Jan. 31, 2022	87,873,141
Beginning Balance at Oct. 31, 2021	$ 879,000	128,437,000	(126,589,000)	2,727,000
Beginning balance, shares at Oct. 31, 2021	87,873,141
Share-based compensation expense - stock options		159,000		159,000
Share-based compensation expense - restricted stock units		21,000		21,000
Issuance of common stock upon the exercise of stock options
Issuance of common stock upon the exercise of stock options, shares
Net loss			(702,000)	(702,000)
Ending Balance at Jan. 31, 2022	$ 879,000	$ 128,617,000	$ (127,291,000)	$ 2,205,000
Ending balance, shares at Jan. 31, 2022	87,873,141

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2022	Jan. 31, 2021
Operating activities
Net loss	$ (702,000)	$ (595,000)	$ (1,498,000)	$ (775,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation			370,000	470,000
Depreciation and amortization			110,000	90,000
Gain on extinguishment of indebtedness			(239,000)
Changes in operating assets and liabilities:
Accounts receivable			162,000	623,000
Inventories			33,000	(71,000)
Prepaid expenses			3,000	(13,000)
Accounts payable and accrued liabilities			(147,000)	(732,000)
Net cash used in operating activities			(1,206,000)	(408,000)
Investing activities
Purchases of property, plant and equipment			(53,000)	(504,000)
Net cash used in investing activities			(53,000)	(504,000)
Net decrease in cash, cash equivalents, and restricted cash			(1,259,000)	(912,000)
Cash, cash equivalents, and restricted cash at beginning of period			2,465,000	3,914,000
Cash, cash equivalents, and restricted cash at end of period	1,206,000	3,002,000	1,206,000	3,002,000
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	1,131,000	2,927,000	1,131,000	2,927,000
Restricted cash	75,000	75,000	75,000	75,000
Total cash, cash equivalents and restricted cash	$ 1,206,000	$ 3,002,000	$ 1,206,000	$ 3,002,000

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jan. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	1. Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of PURE Bioscience, Inc. and its wholly owned subsidiary, ETI H2O Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements. All inter-company balances and transactions have been eliminated. All references to “PURE,” “we,” “our,” “us” and the “Company” refer to PURE Bioscience, Inc. and our wholly owned subsidiary. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information pursuant to the instructions to Form 10-Q and Article 10/Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the quarter ended January 31, 2022 are not necessarily indicative of the results that may be expected for other quarters or the year ending July 31, 2022. The July 31, 2021 balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP and included in our Annual Report on Form 10-K. For more complete information, these unaudited financial statements and the notes thereto should be read in conjunction with the audited financial statements for the year ended July 31, 2021 included in our Annual Report on Form 10-K covering such period filed with the Securities and Exchange Commission, or SEC, on October 28, 2021. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.

Liquidity and Going Concern

Liquidity and Going Concern	6 Months Ended
	Jan. 31, 2022
Liquidity And Going Concern
Liquidity and Going Concern	2. Liquidity and Going Concern We have a history of recurring losses, and as of January 31, 2022 we have incurred a cumulative net loss of $ 127,291,000 1,498,000 917,000 1,259,000 1,131,000 Our future capital requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following: the acceptance of, and demand for, our products; our success and the success of our partners in selling our products; our success and the success of our partners in obtaining regulatory approvals to sell our products; the costs of further developing our existing products and technologies; the extent to which we invest in new product and technology development; and the costs associated with the continued operation, and any future growth, of our business. The outcome of these and other forward-looking factors will substantially affect our liquidity and capital resources. Until we can continually generate positive cash flow from operations, we will need to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot ensure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jan. 31, 2022
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Revenue Recognition We account for revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process: 1. Identify the contract with the customer 2. Identify the performance obligations in the contract 3. Determine the transaction price 4. Allocate the transaction price to the performance obligations in the contract 5. Recognize revenue when (or as) each performance obligation is satisfied Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE ® ® Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price. Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Our direct customer and distributor sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns. Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales. We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A summary of our revenue by product type for the six months ended January 31, 2022 and 2021 is as follows: Summary of Revenue by Product 2022 2021 January 31, 2022 2021 PURE Hard Surface $ 806,000 $ 2,228,000 SILVÉRION 106,000 57,000 Total $ 912,000 $ 2,285,000 A summary of our revenue by product type for the three months ended January 31, 2022 and 2021 is as follows: 2022 2021 January 31, 2022 2021 PURE Hard Surface $ 362,000 $ 841,000 SILVÉRION 53,000 27,000 Total $ 415,000 $ 868,000 Variable Consideration We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Net Loss Per Share Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of January 31, 2022 and 2021, stock options, warrants and shares issuable under restricted stock unit awards of 8,676,625 10,748,765 Schedule of Anti dilutive Securities Excluded from Computation of Earnings Per Share January 31, 2022 2021 Common stock option 7,314,125 8,408,500 Restricted stock units 1,362,500 2,012,500 Warrants — 327,765 Total 8,676,625 10,748,765 Inventory Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold. Inventories consist of the following: Schedule of Inventories January 31, 2022 July 31, 2021 Raw materials $ 17,000 $ 17,000 Finished goods 282,000 315,000 Inventories $ 299,000 $ 332,000 Share-Based Compensation We periodically issue stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. We account for such grants issued and vesting to employees based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. We estimate the fair value of share-based payment awards at the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Impairment of Long-Lived Assets In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. During the three and six months ended January 31, 2022 and 2021, no impairment of long-lived assets was indicated or recorded. Concentrations Gross product sales 14 13 10 18 13 12 15 14 12 20 11 Accounts receivable. 26 11 10 31 Purchases. 19 18 18 16 39 Accounts payable. 29 35 13 Segments We operate in one segment for the manufacture and distribution of our products. In accordance with the “Segment Reporting” Topic of the ASC, our chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Jan. 31, 2022
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	4. Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivable. The standard will replace today’s “incurred loss” approach with an “expected loss” model , under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. As small business filer, the standard will be effective for us for interim and annual reporting periods beginning after December 15, 2022. The Company is currently assessing the impact of adopting this standard on the Company’s financial statements and related disclosures. In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the consolidated financial statements, but currently does not believe ASU 2020-06 will have a significant impact on the Company’s accounting. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The adoption of ASU 2021-04 is not expected to have any impact on the Company’s consolidated financial statement presentation or disclosures. Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

Debt

Debt	6 Months Ended
	Jan. 31, 2022
Debt Disclosure [Abstract]
Debt	5. Debt Receipt of CARES funding In April 2021, we were funded $ 239,000 The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act is eligible to be forgiven provided that (a) the Company uses the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs. 1.0 two year During the six months ended January 31, 2022, we applied and received loan forgiveness under the provisions of the CARES Act for the entire $ 239,000

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Jan. 31, 2022
Equity [Abstract]
Stockholders’ Equity	6. Stockholders’ Equity Restricted Stock Units The Company issues restricted stock unit awards (“RSUs”) to key management and as compensation for services to consultants and others. The RSUs typically vest over a two-year period and carry a ten-year term. Each RSU represents the right to receive one share of common stock, issuable at the time the RSU subsequently settles, as set forth in the Restricted Stock Unit Agreement. The Company determines that fair value of those awards at the date of grant, and amortizes those awards as an expense over the vesting period of the award. The shares earned under the grant are usually issued when the award settles at the end of the term. On October 4, 2018, the Board of Directors appointed Tom Myers as the Company’s Chief Operating Officer. In connection with Mr. Myers appointment, the Board agreed to grant him 500,000 500,000 As of July 31, 2021, the Company had granted 2,012,500 1,679,167 333,333 144,000 During the periods ended January 31, 2022 and 2021, the Company recognized $ 42,000 three year 103,000 333,333 1.24 During the six months ended January 31, 2022, 650,000 1,362,500 1,029,167 A summary of our restricted stock unit activity and related data is as follows: Schedule of Restricted Stock Activity Total RSU Vested and Outstanding at July 31, 2021 2,012,500 1,679,167 Granted — — Issued (650,000 ) (650,000 ) Forfeited — — Outstanding at January 31, 2022 1,362,500 1,029,167 Stock Option Plans 2007 Equity Incentive Plan In February 2016, we amended and restated our 2007 Equity Incentive Plan, the (“2007 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2007 Plan by 4,000,000 February 4, 2026 10 1,552,000 2017 Equity Incentive Plan In January 2021, we amended and restated our 2017 Equity Incentive Plan, the (“2017 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2017 Plan by 5,000,000 10 3,755,000 During the six months ended January 31, 2022, we authorized the issuance of 170,000 36,000 one three years ten year 60,000 48,000 one year five year A summary of our stock option activity is as follows: Schedule of Stock Option Activity Shares Weighted- Price Aggregate Outstanding at July 31, 2021 8,644,125 $ 0.76 $ 124,000 Granted 170,000 $ 0.29 2,000 Exercised — $ — — Cancelled (1,500,000 ) $ 1.13 — Outstanding at January 31, 2022 7,314,125 $ 0.67 $ — The weighted-average remaining contractual term of options outstanding at January 31, 2022 was 5.96 At January 31, 2022, options to purchase 7,314,125 0.67 5.96 242,000 0.91 For the six months ended January 31, 2022 share-based compensation expense for stock options that vested during the period was $ 328,000 428,000 We use the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions: Schedule of Fair Value Assumptions Three Months Ended January 31, 2022 Three Months Ended January 31, 2021 Six Months Ended January 31, 2022 Six Months Ended January 31, 2021 Volatility 90.26 % 104.93 % 88.35 % 104.93 % Risk-free interest rate 1.36 % 0.18 % 1.17 % 0.18 % Dividend yield 0.0 % 0.0 % 0.0 % 0.0 % Expected life 5.31 2.81 5.59 2.81 Volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation. The expected life of options was estimated using the average between the contractual term and the vesting term of the options.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jan. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions As of January 31, 2022 and January 31, 2021, accounts payable include $ 134,000 64,047

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jan. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies COVID-19 The COVID-19 pandemic has led to severe disruptions in general economic activities, as businesses and federal, state, and local governments take increasingly broad actions to mitigate this public health crisis. While we have experienced some delays related to final third-party validation of certain of our products and product rollouts by customers using PURE Control, we have not experienced a material disruption to our business. In addition, we previously benefited from increased demand from our customers for our PURE Hard Surface product due to a focus on surface disinfecting in response to attempting to prevent COVID-19 transmission. We subsequently experienced an abatement in such demand and cannot assure you that demand will stabilize. Additionally, we are beginning to experience supply chain issues with our various plastic packaging configurations and citric acid. Further, on a go-forward basis, we cannot guarantee the overall economic conditions will not affect our business, as these conditions may significantly negatively impact all aspects of our business. Our business is dependent on the continued health and productivity of our employees, including our sales staff and corporate management team. Additionally, our liquidity could be negatively impacted if these conditions continue for a significant period of time and we may be required to pursue additional sources of financing to obtain working capital, maintain appropriate inventory levels, and meet our financial obligations. Currently, capital and credit markets have been disrupted by the crisis and our ability to obtain any required financing is not guaranteed and largely dependent upon evolving market conditions and other factors. Depending on the continued impact of the crisis, further actions may be required to improve our cash position and capital structure. The extent to which the COVID-19 pandemic ultimately impacts our business, sales, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume and, more specifically, the effect it has on our customers and suppliers. Even after the COVID-19 pandemic has subsided, we may experience significant impacts to our business as a result of its global economic impact, including any economic downturn or recession that has occurred or may occur in the future.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Jan. 31, 2022
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition We account for revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process: 1. Identify the contract with the customer 2. Identify the performance obligations in the contract 3. Determine the transaction price 4. Allocate the transaction price to the performance obligations in the contract 5. Recognize revenue when (or as) each performance obligation is satisfied Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE ® ® Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price. Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Our direct customer and distributor sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns. Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales. We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A summary of our revenue by product type for the six months ended January 31, 2022 and 2021 is as follows: Summary of Revenue by Product 2022 2021 January 31, 2022 2021 PURE Hard Surface $ 806,000 $ 2,228,000 SILVÉRION 106,000 57,000 Total $ 912,000 $ 2,285,000 A summary of our revenue by product type for the three months ended January 31, 2022 and 2021 is as follows: 2022 2021 January 31, 2022 2021 PURE Hard Surface $ 362,000 $ 841,000 SILVÉRION 53,000 27,000 Total $ 415,000 $ 868,000 Variable Consideration We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.
Net Loss Per Share	Net Loss Per Share Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of January 31, 2022 and 2021, stock options, warrants and shares issuable under restricted stock unit awards of 8,676,625 10,748,765 Schedule of Anti dilutive Securities Excluded from Computation of Earnings Per Share January 31, 2022 2021 Common stock option 7,314,125 8,408,500 Restricted stock units 1,362,500 2,012,500 Warrants — 327,765 Total 8,676,625 10,748,765
Inventory	Inventory Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold. Inventories consist of the following: Schedule of Inventories January 31, 2022 July 31, 2021 Raw materials $ 17,000 $ 17,000 Finished goods 282,000 315,000 Inventories $ 299,000 $ 332,000
Share-Based Compensation	Share-Based Compensation We periodically issue stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. We account for such grants issued and vesting to employees based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. We estimate the fair value of share-based payment awards at the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. During the three and six months ended January 31, 2022 and 2021, no impairment of long-lived assets was indicated or recorded.
Concentrations	Concentrations Gross product sales 14 13 10 18 13 12 15 14 12 20 11 Accounts receivable. 26 11 10 31 Purchases. 19 18 18 16 39 Accounts payable. 29 35 13
Segments	Segments We operate in one segment for the manufacture and distribution of our products. In accordance with the “Segment Reporting” Topic of the ASC, our chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	6 Months Ended
	Jan. 31, 2022
Accounting Policies [Abstract]
Summary of Revenue by Product	A summary of our revenue by product type for the six months ended January 31, 2022 and 2021 is as follows: Summary of Revenue by Product 2022 2021 January 31, 2022 2021 PURE Hard Surface $ 806,000 $ 2,228,000 SILVÉRION 106,000 57,000 Total $ 912,000 $ 2,285,000 A summary of our revenue by product type for the three months ended January 31, 2022 and 2021 is as follows: 2022 2021 January 31, 2022 2021 PURE Hard Surface $ 362,000 $ 841,000 SILVÉRION 53,000 27,000 Total $ 415,000 $ 868,000
Schedule of Anti dilutive Securities Excluded from Computation of Earnings Per Share	Schedule of Anti dilutive Securities Excluded from Computation of Earnings Per Share January 31, 2022 2021 Common stock option 7,314,125 8,408,500 Restricted stock units 1,362,500 2,012,500 Warrants — 327,765 Total 8,676,625 10,748,765
Schedule of Inventories	Inventories consist of the following: Schedule of Inventories January 31, 2022 July 31, 2021 Raw materials $ 17,000 $ 17,000 Finished goods 282,000 315,000 Inventories $ 299,000 $ 332,000

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	6 Months Ended
	Jan. 31, 2022
Equity [Abstract]
Schedule of Restricted Stock Activity	A summary of our restricted stock unit activity and related data is as follows: Schedule of Restricted Stock Activity Total RSU Vested and Outstanding at July 31, 2021 2,012,500 1,679,167 Granted — — Issued (650,000 ) (650,000 ) Forfeited — — Outstanding at January 31, 2022 1,362,500 1,029,167
Schedule of Stock Option Activity	A summary of our stock option activity is as follows: Schedule of Stock Option Activity Shares Weighted- Price Aggregate Outstanding at July 31, 2021 8,644,125 $ 0.76 $ 124,000 Granted 170,000 $ 0.29 2,000 Exercised — $ — — Cancelled (1,500,000 ) $ 1.13 — Outstanding at January 31, 2022 7,314,125 $ 0.67 $ —
Schedule of Fair Value Assumptions	Schedule of Fair Value Assumptions Three Months Ended January 31, 2022 Three Months Ended January 31, 2021 Six Months Ended January 31, 2022 Six Months Ended January 31, 2021 Volatility 90.26 % 104.93 % 88.35 % 104.93 % Risk-free interest rate 1.36 % 0.18 % 1.17 % 0.18 % Dividend yield 0.0 % 0.0 % 0.0 % 0.0 % Expected life 5.31 2.81 5.59 2.81

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2022	Jan. 31, 2021	Jul. 31, 2021
Liquidity And Going Concern
Cumulative net loss	$ 127,291,000		$ 127,291,000		$ 125,793,000
Net loss	702,000	$ 595,000	1,498,000	$ 775,000
Revenue	416,000	916,000	917,000	2,507,000
Net cash provided by (used) in operating and investing activities			1,259,000
Cash and cash equivalents	$ 1,131,000	$ 2,927,000	$ 1,131,000	$ 2,927,000	$ 2,390,000

Summary of Revenue by Product (

Summary of Revenue by Product (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2022	Jan. 31, 2021
Product Information [Line Items]
Total	$ 415,000	$ 868,000	$ 912,000	$ 2,285,000
PURE Hard Surface [Member]
Product Information [Line Items]
Total	362,000	841,000	806,000	2,228,000
SILVERION [Member]
Product Information [Line Items]
Total	$ 53,000	$ 27,000	$ 106,000	$ 57,000

Schedule of Anti dilutive Secur

Schedule of Anti dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	6 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	8,676,625	10,748,765
Common Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	7,314,125	8,408,500
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	1,362,500	2,012,500
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities		327,765

Schedule of Inventories (Detail

Schedule of Inventories (Details) - USD ($)	Jan. 31, 2022	Jul. 31, 2021
Accounting Policies [Abstract]
Raw materials	$ 17,000	$ 17,000
Finished goods	282,000	315,000
Inventories	$ 299,000	$ 332,000

Significant Accounting Polici_4

Significant Accounting Policies (Details Narrative) - shares	3 Months Ended		6 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2022	Jan. 31, 2021
Product Information [Line Items]
Dilutive common share			8,676,625	10,748,765
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Two Customers [Member]
Product Information [Line Items]
Concentration risk percentage	14.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Individual Customer One [Member]
Product Information [Line Items]
Concentration risk percentage	13.00%	15.00%	18.00%	20.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Individual Customer Two [Member]
Product Information [Line Items]
Concentration risk percentage	10.00%	14.00%	13.00%	11.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Individual Customer Three [Member]
Product Information [Line Items]
Concentration risk percentage		12.00%	12.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]
Product Information [Line Items]
Concentration risk percentage			26.00%	31.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Two [Member]
Product Information [Line Items]
Concentration risk percentage			11.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Three [Member]
Product Information [Line Items]
Concentration risk percentage			10.00%
Customer Concentration Risk [Member] | Purchases [Member] | Vendor One [Member]
Product Information [Line Items]
Concentration risk percentage	19.00%	18.00%	18.00%	39.00%
Customer Concentration Risk [Member] | Purchases [Member] | Vendor Two [Member]
Product Information [Line Items]
Concentration risk percentage		16.00%
Customer Concentration Risk [Member] | Accounts Payable [Member] | Vendor One [Member]
Product Information [Line Items]
Concentration risk percentage			29.00%	35.00%
Customer Concentration Risk [Member] | Accounts Payable [Member] | Vendor Two [Member]
Product Information [Line Items]
Concentration risk percentage				13.00%

Debt (Details Narrative)

Debt (Details Narrative) - California Bank and Trust [Member] - Payroll Protection Program [Member] - USD ($)	Apr. 30, 2021	Apr. 30, 2021	Jan. 31, 2022
Line of Credit Facility [Line Items]
Net proceeds from payroll protection program loan		$ 239,000	$ 239,000
Debt description		The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act is eligible to be forgiven provided that (a) the Company uses the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs.
Debt instrument interest percentage	1.00%	1.00%
Debt instrument term	2 years

Schedule of Restricted Stock Ac

Schedule of Restricted Stock Activity (Details)	6 Months Ended
	Jan. 31, 2022shares
Total RSU Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, Beginning balance	2,012,500
Granted
Issued	(650,000)
Forfeited
Outstanding, Ending balance	1,362,500
Vested and Issuable [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, Beginning balance	1,679,167
Granted
Issued	(650,000)
Forfeited
Outstanding, Ending balance	1,029,167

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - 2017 Equity Incentive Plan [Member] - USD ($)	6 Months Ended
	Jan. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding Shares, Beginning Balance	8,644,125
Weighted- Average Exercise Price Outstanding, Beginning Balance	$ 0.76
Aggregate Intrinsic Value Outstanding, Beginning Balance	$ 124,000
Options Granted, Shares	170,000
Weighted- Average Exercise Price Granted	$ 0.29
Aggregate Intrinsic Value Outstanding, Granted	$ 2,000
Options Exercised, Shares
Weighted- Average Exercise Price Exercised
Options Expired, Shares	(1,500,000)
Weighted- Average Exercise Price Cancelled	$ 1.13
Options Outstanding Shares, Ending Balance	7,314,125
Weighted- Average Exercise Price Outstanding, Ending Balance	$ 0.67
Aggregate Intrinsic Value Outstanding, Ending Balance

Schedule of Fair Value Assumpti

Schedule of Fair Value Assumptions (Details)	3 Months Ended		6 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2022	Jan. 31, 2021
Equity [Abstract]
Volatility	90.26%	104.93%	88.35%	104.93%
Risk-free interest rate	1.36%	0.18%	1.17%	0.18%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Expected life	5 years 3 months 21 days	2 years 9 months 21 days	5 years 7 months 2 days	2 years 9 months 21 days

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	Oct. 04, 2018	Jul. 31, 2021	Jan. 31, 2021	May 31, 2020	Feb. 29, 2016	Jan. 31, 2022	Jan. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation						$ 328,000	$ 428,000
Unrecognized non-cash compensation costs						$ 242,000
Weighted average contractual term						5 years 11 months 15 days
Options issued to purchase common stock exercisable						7,314,125
Weighted average exercise price						$ 0.67
Weighted average contractual term						5 years 11 months 15 days
Weighted average contractual term grants						10 months 28 days
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, vesting period						1 year
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, vesting period						3 years
2007 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, vesting period					10 years
Common stock shares increase under the plan					4,000,000
Share-based compensation, expiration date					Feb. 4, 2026
Number of shares available for issuance under the plan						1,552,000
2017 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, vesting period			10 years
Common stock shares increase under the plan			5,000,000
Number of shares available for issuance under the plan						3,755,000
New Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock option authorized fair value			$ 48,000				$ 48,000
Share-based compensation, vesting period						10 years	5 years
Number of stock option authorized for issuance			60,000			170,000	60,000
Fair value of stock option						$ 36,000
New Employees [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, vesting period							1 year
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of units, vested		1,679,167				650,000
Restricted stock options, granted		2,012,500
Number of stock option authorized fair value		$ 333,333
Number of shares authorized remained unvested		144,000
Share-based compensation						$ 42,000	$ 42,000
Share-based compensation, vesting period						3 years
Unrecognized non-cash compensation costs						$ 103,000
Number of restricted stock shares						333,333
Weighted average period, restricted stock						1 year 2 months 26 days
Restricted Stock Units (RSUs) [Member] | Vested and Issuable [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of units, vested						1,362,500
Number of units, vested and issuable						1,029,167
Restricted Stock Units (RSUs) [Member] | Mr. Myers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of units, vested	500,000			500,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jan. 31, 2022	Jul. 31, 2021	Jan. 31, 2021
Accounts payable	$ 425,000	$ 593,000
Board Fees due to Officers and Directors [Member]
Accounts payable	$ 134,000		$ 64,047